Treatment-resistant depression (TRD) is a leading cause of global long-term disability. COS’s Senior Director, Biostatistics, Lysbeth Floden and CEO Stacie Hudgens have co-authored this newly published manuscript on the Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant https://link.springer.com/article/10.1007/s40263-022-00916-2#article-info

Clinical Outcomes Solutions (‘COS’), a global leader in the collection, analysis and reporting of patient-centred outcomes data with offices in Folkestone (UK), and Tucson and Chicago (USA), today marks five years of partnering collaboratively with FingerPost, a leading consultancy providing market-specific payer and Health Technology Assessment (HTA) insights and intelligence worldwide.    Established in 2013, COS is a global leader in …